Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Biopharma.

    Client Virtual Booth

    BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Biopharma
    Ukraine Flag
    Country
    Country
    Ukraine
    Address
    Address
    12, Mykoly Amosova str.
    Telephone
    Telephone
    +38 (044) 277-36-10
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biopharma.com.ua/en/home-page/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries

    Details:

    Oxbryta is a once-daily, oral therapy that directly inhibits hemoglobin polymerization for the treatment of SCD. Biopharma-MEA will distribute Oxbryta® (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.


    Lead Product(s): Voxelotor

    Therapeutic Area: Genetic Disease Product Name: Oxbryta

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Global Blood Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 08, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Biopharma Starts Clinical Trials on Possible Treatment for COVID-19

    Details:

    The firm is using immunoglobulin, or antibodies made from the plasma cells of patients who have fully recovered from COVID-19


    Lead Product(s): Immunoglobulin G 285-292

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search